OVM Pipeline Oct-22

The graphic above shows the research and development plans for Oxford Vacmedix UK. 

  • OVM-100 is a cancer vaccine targeting HPV related tumours such as cervical cancer and head and neck cancer,
  • OVM-200 is a cancer vaccine targeting survivin (inhibitor of apoptosis protein) over expressed in most solid tumours including lung, breast, prostate and ovarian cancers.

For more information, please contact us using the contact form on this website.